{"id":"tp-43492","type":"article-newspaper","title":"Ligand Pharmaceuticals Raises 2026 Adjusted EPS Outlook After Q3 Beat","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/43492","datePublished":"2026-10-29T12:11:42.000Z","dateModified":"2026-10-29T12:11:42.000Z","language":"en","abstract":"The company lifted its adjusted earnings per diluted share range to about $9.50 to $9.75 while keeping its $270 million to $310 million revenue forecast unchanged.","section":"Business","references":[]}